Close Menu

Bruker

The companies will determine the test's suitability as an in vitro diagnostic for SARS-CoV-2 to be run on Bruker's MALDI-TOF instruments in the UK and Europe.

The company aims to transition its NMR-based platform from research to clinical use and is exploring areas including kidney and liver disease and neurology.

The PCR-based panel is designed to simultaneously detect SARS-CoV-2, influenza A and B, and respiratory syncytial virus, with results in less than two hours.

ArcDia's agreement with Bruker subsidiary Hain Lifescience is exclusive in Germany, Austria, Switzerland, Belgium, the Netherlands, and Luxembourg.

The FluoroType SARS-CoV-2 plus real-time PCR test can distinguish SARS-CoV-2 from other coronaviruses that can cause the common cold.

The deal took effect immediately and shipments have to Spain, France, Germany, and the UK have begun.

News items for the in vitro diagnostics industry for the week of Feb. 17, 2020. 

The instrument's ability to run in negative-ion mode allows it to move beyond its traditional focus on proteins and into the analysis of other analyte classes.

Get the latest news from Bruker, Veracyte, Natera, VolitionRx, Celcuity, Genome Diagnostics, Verogen, iGene Labs, and Danaher for the week of 5/10/19.

Pages